| ANRO Stock | | | 23.27 2.39 11.45% |
Use the math operators workspace to apply Price Series Multiplication operator and other studies to Alto Neuroscience and DBV Technologies. The focus on relative price relationships between Alto Neuroscience and DBV Technologies helps organize trend, volatility, and risk context for Alto Neuroscience and DBV Technologies.
Most technical analysis of Alto Neuroscience help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Alto from various momentum indicators to cycle indicators. When you analyze Alto charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
The stock is currently in an active downward rally.Alto Neuroscience maintains exchange-traded status on the New York Stock Exchange. As a small-cap equity, Alto Neuroscience is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/B of 5.81. Alto Neuroscience has market cap of 648.67 M, ROE of -45.01%.
Methodology
Unless otherwise specified, financial data for Alto Neuroscience is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Alto (USA Stocks:ANRO) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs rely on public filings and market reference sources and institutional disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR. Publication cadence can introduce timing differences. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Alto Neuroscience is covered by 10 analysts. 5 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Evercore ISI, Morgan Stanley, BMO Capital Markets, Oppenheimer & Co., Guggenheim Securities, HSBC Global Research, Raymond James, Bernstein Research, among others. Updates may occur throughout the day.
Tracking Alto Neuroscience inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.